Lilly Asia Ventures has returned for genetic testing startup Veritas Genetics' series B round, where it was joined by Jiangsu Simcere Pharmaceutical.
Veritas Genetics, a US-based genetic testing technology producer spun out of Harvard University, has raised $30m in series B capital from investors including drug developer Jiangsu Simcere Pharmaceutical.
Lilly Asia Ventures, a corporate venturing subsidiary of pharmaceutical company Eli Lilly, also contributed to the round, which was led by growth equity firm Trustbridge Partners.
Sean Cao, CEO of Simcere in the US until this month, now managing director of C-Bridge Capital Partners, said: “This was not the first deal by Simcere. We…
